David Baltimore - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Dr. David Baltimore, Ph.D., is an Independent Director of Amgen Inc. David Baltimore is President Emeritus and Robert Andrews Millikan Professor of Biology at the California Institute of Technology, or Caltech. He received the Nobel Prize in Medicine as a corecipient in 1975. Dr. Baltimore was a director of Regulus Therapeutics Inc., a biopharmaceutical company, since 2007, serving on its Compensation Committee and chairing its Nominating and Governance Committee, and is a member of its scientific advisory board
Age: 78  Director Since 1999  Ph.D    
805-447-1000  http://www.amgen.com
Baltimore has also been a member of the board of directors of Immune Design Corporationrationration, a clinicalstage immunotherapy company, since 2008, chairing its Nominating and Governance Committee, and is a member of its scientific advisory board. He was a director of BB Biotech, AG, a Swiss investment company, from 1994 to March 2011 and served as a director of MedImmune, Inc., a privatelyheld antibody formulation company, from 2003 until its acquisition by AstraZeneca plc, a pharmaceutical and biotechnology company, in 2007. In 2008, Dr. Baltimore became a founder of Calimmune, Inc., a privatelyheld clinicalstage gene therapy company, and served as Chairman of the board of directors until November 2015.

David Baltimore Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Robert KidderMerck Co
William KaelinEli Lilly and Company
Todd SisitskyEndo International plc
Phebe NovakovicAbbott Laboratories
Joseph ZaccagninoMallinckrodt Public Limited Com
Catherine KlemaAllergan plc
Inge ThulinMerck Co
Melinda LitherlandBio Rad Laboratories
Marschall RungeEli Lilly and Company
David HooverEli Lilly and Company
Jose BaselgaBristol Myers Squibb Company
Leslie BrunMerck Co
Arthur HigginsEndo International plc
Michelle KumbierAbbott Laboratories
Adriane BrownAllergan plc
Terrence KearneyVertex Pharmaceuticals Incorpor
Rochelle LazarusMerck Co
Kathi SeifertEli Lilly and Company
Carol DavidsonAllergan plc
Anne WhitakerMallinckrodt Public Limited Com
Michael HyattEndo International plc

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.